Leading dementia researcher joins Brain+

Brain+ adds new clinical and development competences To accelerate and support market access of its digital dementia product portfolio Rising star clinical dementia researcher to join the company in a new position as Clinical Director […]

DETAIL

CST Therapist Companion advancing

Brain+ further advances its first digital dementia product, Cognitive Stimulation Therapy (CST) – Therapist Companion Commercial launch in Denmark will be November 1, 2022 Adaptation of a UK product version for the United Kingdom starts […]

DETAIL

Brain+ begins early activity and brand building in the US

Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and […]

DETAIL

First milestone met

Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch.  Meeting this milestone unlocks access for Brain+ to additional […]

DETAIL

New Research report values Brain+

New research report values Brain+ at DKK 4.1 per share in the base case, and DKK 6.4 in the bull case. The research report concludes that “Brain+ is in a strong position to grow towards […]

DETAIL

Accelerated launch Q2 2023

  Brain+ partners with German medical distributor Advances launch of its first CST dementia product in Germany to Q2 2023   Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in […]

DETAIL

Brain+’ new product for dementia launching Q4 2022

  Brain+’ new product for dementia launching Q4 2022     Digital “CST–Therapist Companion” is launching one year ahead of plan   The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy […]

DETAIL

Growing interest in DTx from big pharma

Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other […]

DETAIL

Common Nordic digital health evaluation framework launched

Common Nordic digital health evaluation framework launched Digital Therapeutics (DTx) is a growing trend and is increasingly a recognized market providing an important supplement to the established trillion USD pharmaceutical market (traditional medicine).  The DTx […]

DETAIL

Germany opens the DiPA reimbursement pathway

Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST A significant event for Brain+ as […]

DETAIL